Preclinical Pharmacokinetics, Interspecies Scaling, and Tissue Distribution of a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis and in pathological processes such as tumor growth, rheumatoid arthritis, and ocular neovascularization. A recombinant humanized monoclonal antibody (rhuMAb), rhuMAb VEGF, has been developed to inhibit the effects of VEGF in the treatment of solid tumors. Intravenous and s.c. pharmacokinetic studies were conducted in mice, rats, and cynomolgus monkeys. In addition, the tissue distribution of i.v. 125I-rhuMAb VEGF was investigated in rabbits. At a dose of approximately 10 mg/kg, the clearance of rhuMAb VEGF from the serum was 15.7 ml/day/kg in mice, 4.83 ml/day/kg in rats, and 5.59 ml/day/kg in cynomolgus monkeys, and the terminal half-life ranged from 6 to 12 days in all species. After s.c. administration, rhuMAb VEGF had a bioavailability of 69% in rats and 100% in mice and cynomolgus monkeys. Pharmacokinetic data in mice, rats, and cynomolgus monkeys were used to predict the pharmacokinetics of rhuMAb VEGF using allometric scaling in humans. The predicted serum clearance of rhuMAb VEGF in humans was 2.4 ml/day/kg and the terminal half-life was 12 days. Two hours after i.v. bolus administration of 125I-rhuMAb VEGF in rabbits, trichloroacetic acid-precipitable radioactivity was noted primarily in the plasma, with lesser amounts in highly perfused tissues such as kidneys, testes, spleen, heart, and lungs. At 48 h after dosing, trichloroacetic acid-precipitable radioactivity was noted in plasma with minimal distribution to testes, bladder, heart, lungs, and kidneys. Tissue distribution and pharmacokinetic data indicate that rhuMAb VEGF is cleared slowly and distributes to specific sites in the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationBaselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Warren, R. S., Yuan, H., Matli, M. R., Gillett, N. A., & Ferrara, N. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117857 · Cited by 694
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648
Adamis, A. P. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100130062010 · Cited by 635
Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., Senger, D. R., Connolly, J. L., & Schnitt, S. J. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90119-1 · Cited by 619
Fava, R. A., Olsen, N. J., Spencer-Green, G., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Senger, D. R., Dvorak, H. F., & Brown, L. F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.341 · Cited by 520
Gasparini, G., Bonoldi, E., Gatti, C., Vinante, O., Toi, M., Tominaga, T., Gion, M., Dittadi, R., Verderio, P., Boracchi, P., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.2.139 · Cited by 494
Jakeman, L. B., Winer, J., Bennett, G. L., Altar, C. A., & Ferrara, N. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115568 · Cited by 433
The role of vascular endothelial growth factor in pathological angiogenesis
Ferrara, N. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666035 · Cited by 414
Man versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 388
Takano, S., Yoshii, Y., Kondo, S., Suzuki, H., MARUNO, T., SHIRAI, S., & Nose, T. (1996) · PubMed · Cited by 334
Asano, M., Yukita, A., Matsumoto, T., Kondo, S., & Suzuki, H. (1995) · PubMed · Cited by 256
Yamamoto, Y., Toi, M., Kondo, S., Matsumoto, T., Suzuki, H., Kitamura, M., Tsuruta, K., Taniguchi, T., Okamoto, A., Mori, T., et al. (1996) · PubMed · Cited by 244
Nakajo, M., Shapiro, B., Copp, J., Kalff, V., Gross, M. D., Sisson, J. C., & Beierwaltes, W. H. (1983) · PubMed · Cited by 224
Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins
Mordenti, J., Chen, S. A., Moore, J. A., Ferraiolo, B. L., & Green, J. D. (1991) · Pharmaceutical Research · doi:10.1023/a:1015836720294 · Cited by 191
Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Salvén, P., Mänpää, H., Orpana, A., Alitalo, K. K., & Joensuu, H. (1997) · PubMed · Cited by 188
Baxter, L. T., Zhu, H. J., Mackensen, D. G., Butler, W. F., & Jain, R. K. (1995) · PubMed · Cited by 180
Fox, J. A., Hotaling, T. E., Struble, C. B., Ruppel, J., Bates, D. J., & Schoenhoff, M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21215-0 · Cited by 123
Extrapolation of Toxicological and Pharmacological Data from Animals to Humans
Chappell, W. R., & Mordenti, J. J. (1991) · Advances in Drug Research · doi:10.1016/b978-0-12-013320-8.50005-8 · Cited by 116
Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R. S., Lin, P., Weber, D. V., & Spence, C. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.4.1352 · Cited by 103
Lavé, T., Levet‐Trafit, B., Schmitt‐Hoffmann, A. H., Morgenroth, B., Richter, W., & Chou, R. C. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600841106 · Cited by 41
Davis, C. B., Hepburn, T. W., Urbanski, J. J., Kwok, D. C., Hart, T. K., Herzyk, D. J., Demuth, S. G., Leland, M., & Rhodes, G. R. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06744-3 · Cited by 33
The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus*1
MATSUZAWA, K. (1992) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(92)90024-c · Cited by 7
Cited by
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
Metadata
- Authors
- Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1999-01
- Volume
- 288
- Issue
- 1
- Pages
- 371-378
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1900061753
- Cited by
- 255
- References
- 29
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.